Skip to main content
2025 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Preclinical, Clinical, and Translational Sciences
Chalk Talk

Integrated Preclinical CRO Strategies: From Target Engagement to IND

Monday, November 10, 2025
11:15 AM - 12:00 PM CT
Location:Spotlight Stage B, Aisle 2500, Exhibit Hall

Sponsored By 
Preclinical & Translation Sciences Partner Presentation-Preclinical

Description: Drug metabolism and phamacokenetics (DMPK) studies play important role in drug discovery. Utalizing DMPK assays at early stage (hit to lead, lead to candidate, and IND filing stages ) is critical to move drug candidates to clinical trials. At the hit to lead stage, high throughput ADME assays can screen thousands of chemicals and select final 10-20 relative stable and less drug and drug interation leads, with the combination of the efficacy data, can move leads to the next stage for further development. The session will talk about how to use ADME assays at different stages to select and nominate final candidates to the clinical trials.

Learning Objectives:

  • Understand how to use DMPK assays at different stages to help select leads and candidates in early drug discovery.
  • Explore ADME assay applications for emerging modalities such as ADC, PROTACs, SiRNA, CAR-T in preclinical research.
  • Identify best practices in leveraging pharmacology, DMPK, and toxicology platforms to nominate candidates to clinical trials.